Chief Executvie Officer
Andreas, is the founding Chief Executive Officer (CEO) of Nanomerics. He has a track record in medicines development in industry and academia. Trained as a veterinary surgeon, Andreas during his PhD/DVM worked on the transdermal 'transfersome' drug delivery technology and then became part of the Munich start-up IDEA commercializing the technology.
He later on returned to academia at the Beatson Laboratories, Glasgow, where he became leader of the Cancer Research UK’s ‘Experimental Therapeutics and Gene Medicines’ Group. At Glasgow he also set-up the Analytical Services Unit to support GCLP analysis and was involved in the early clinical development of a number of novel anti-cancer therapies and nanomedicines.
His academic research, supported by grant income of over £10 m, and has been repeatedly featured in the media (TV, radio, print). In addition to being CEO of Nanomerics, Andreas holds a Chair in Translational Therapeutics at University College London, where he also has an active research group focused on the translation of novel nanomedicines and anti-cancer therapies.